Opening New Frontiers By Advancing The Promise of PI Signaling Pathways

Stephen V. Frye, Ph.D.

Select a team to find out more

Stephen V. Frye, Ph.D.

Stephen V. Frye, Ph.D.

Fred Eshelman Distinguished Professor, Director, Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill.

As director of the Center for Integrative Chemical Biology and Drug Discovery at the University of North Carolina at Chapel Hill, Dr. Stephen Frye plays a key role in translational research through collaborative drug discovery projects with other university faculty.  The center has also initiated a program in the area of chemical biology of chromatin regulation.

Stephen has a broad background in drug discovery and development.  He co-invented a marketed product (Avodart) and created a department while working at GlaxoSmithKline credited with discovering the FDA-approved kinase inhibitor oncology therapies, Lapatinib and Pazopanib.   Since he joined UNC in 2007, the Center for Integrative Chemical Biology and Drug Discovery has been designated as one of the National Cancer Institute’s chemical biology centers.  Also, the center has published the first papers on small molecule ligands for methyl-lysine binding domains, and developed an international network of collaborators to increase the annotation and utility of UNC chromatin directed chemical probes.

Stephen has extensive experience leading collaborative science at the national and international level having served as the world-wide Vice President of Discovery Medicinal Chemistry at GlaxoSmithKline, and more recently by contributing to the chemical probe discovery efforts of the Structural Genomics Consortium in Toronto and Oxford.  Stephen serves on several non-profit boards including: Chair of Cancer Research UK’s Drug Discovery Committee; Member of A*STAR Project Review Committee of the Experimental Therapeutics Center, Singapore; Co-Founder and Vice President of the Academic Drug Discovery Consortium; and Member of the SAB for the Spanish National Cancer Research Center.

Stephen received a Ph.D. in organic chemistry from UNC Chapel Hill under the mentorship of the late Prof. Ernest Eliel.  He is the author of over 100 patents and publications.